Literature DB >> 9184477

Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?

M M Teixeira1, R W Gristwood, N Cooper, P G Hellewell.   

Abstract

Phosphodiesterase type 4 (PDE4) plays a major role in modulating the activity of virtually all cells involved in the inflammatory process. Inhibitors of this enzyme family display impressive anti-inflammatory and disease-modifying effects in a variety of experimental models. In this review, Mauro Teixeira, Robert Gristwood, Nicola Cooper and Paul Hellewell examine the capacity of PDE4 inhibitors to exert anti-inflammatory actions in vivo and discuss the potential of this class of drugs to take their place as novel therapeutic agents for a variety of inflammatory diseases.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9184477     DOI： 10.1016/s0165-6147(97)01049-3

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  52 in total

1.  A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.

Authors:  N Cooper; M M Teixeira; J Warneck; J M Miotla; R E Wills; D M Macari; R W Gristwood; P G Hellewell
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

2.  Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)-induced microvascular permeability change in mouse skin.

Authors:  K Irie; E Fujii; H Ishida; K Wada; T Suganuma; T Nishikori; T Yoshioka; T Muraki
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

3.  Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.

Authors:  Ying Xiong; Hai-Ting Lu; Yongjian Li; Guang-Fu Yang; Chang-Guo Zhan
Journal:  Biophys J       Date:  2006-09-01       Impact factor: 4.033

4.  Inhibition of inositol 1,4,5-trisphosphate-induced Ca2+ release by cAMP-dependent protein kinase in a living cell.

Authors:  S Tertyshnikova; A Fein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

5.  Enhancement of the anti-inflammatory and anti-arthritic effects of theophylline by a low dose of a nitric oxide donor or non-specific nitric oxide synthase inhibitor.

Authors:  Adel Gomaa; Mohsen Elshenawy; Noha Afifi; Eman Mohammed; Romany Thabit
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

6.  Hyperalgesia and edema responses induced by rat peripheral blood mononuclear cells incubated with carrageenin.

Authors:  M A De Resende; W G Pimenta Dos Rei; L S Pereira; W Ferreira; M H Perez Garcia; M M Santoro; J Nogueira de Francischi
Journal:  Inflammation       Date:  2001-10       Impact factor: 4.092

7.  Ferulic acid prevents LPS-induced up-regulation of PDE4B and stimulates the cAMP/CREB signaling pathway in PC12 cells.

Authors:  Hao Huang; Qian Hong; Hong-Ling Tan; Cheng-Rong Xiao; Yue Gao
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

8.  Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.

Authors:  Bibiana Bielekova; Nancy Richert; Thomas Howard; Amy N Packer; Gregg Blevins; Joan Ohayon; Henry F McFarland; Claus-Steffen Stürzebecher; Roland Martin
Journal:  Mult Scler       Date:  2009-09-23       Impact factor: 6.312

9.  Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B.

Authors:  Ren Zhang; Eleftheria Maratos-Flier; Jeffrey S Flier
Journal:  Endocrinology       Date:  2009-04-09       Impact factor: 4.736

10.  A Cell-based beta-Lactamase Reporter Gene Assay for the CREB Signaling Pathway.

Authors:  Menghang Xia; Vicky Guo; Ruili Huang; James Inglese; Marshall Nirenberg; Christopher P Austin
Journal:  Curr Chem Genomics       Date:  2009-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.